Summary. A securities fraud class action is a specialized proceeding with its own pleading rules, gatekeeping mechanisms, and a damages model that can exceed a company's market capitalization. This article covers the elements of a Rule 10b-5 claim — materiality, scienter and the strong inference test, and the reliance presumption with its price impact rebuttal — then the PSLRA's heightened pleading, discovery stay, lead plaintiff process, and safe harbor. Later sections address Securities Act claims requiring no scienter, opinion statements after Omnicare, omissions after Macquarie, certification, damages, settlement, and D&O insurance.

A mid-cap medical device company misses its quarterly revenue guidance by eleven percent. The stock falls 34 percent in a day. Within nine days, three complaints are filed.

The complaints do not allege that anyone lied about revenue. They allege that during the prior two quarters, while the company repeatedly described demand as "robust" and its distributor channel as "healthy," it was in fact aware that its two largest distributors were carrying six months of unsold inventory — a fact disclosed for the first time in the earnings call that preceded the drop.

The company's position is that "robust" is puffery, that distributor inventory levels were disclosed in a risk factor, and that nobody lied about anything.

That may be right. But the case will not be decided on whether anyone lied. It will be decided on whether the complaint pleads facts giving rise to a strong inference of scienter that is at least as compelling as any innocent explanation; on whether the challenged statements are actionable or protected as puffery or forward-looking; and on whether the plaintiff can establish price impact at class certification.

Those are three procedural gates, and a securities case that clears all three is worth a great deal more than one that does not — regardless of what actually happened.

The short answer

The claim. Section 10(b) of the Exchange Act, 15 U.S.C. § 78j(b), and SEC Rule 10b-5, 17 C.F.R. § 240.10b-5, prohibit, in connection with the purchase or sale of any security, employing a device or scheme to defraud, making an untrue statement of material fact or omitting a material fact necessary to make statements made not misleading, and engaging in any act or practice that operates as a fraud.

Six elements, from Dura Pharmaceuticals, Inc. v. Broudo, 544 U.S. 336 (2005), and Halliburton Co. v. Erica P. John Fund, Inc., 573 U.S. 258 (2014):

  1. A material misrepresentation or omission;
  2. Scienter;
  3. A connection with the purchase or sale of a security;
  4. Reliance;
  5. Economic loss; and
  6. Loss causation.

The private right of action is implied, not statutory, and the Supreme Court has repeatedly declined to expand it — most significantly by rejecting aiding and abetting liability in Central Bank of Denver v. First Interstate Bank of Denver, 511 U.S. 164 (1994), and scheme liability against secondary actors in Stoneridge Investment Partners, LLC v. Scientific-Atlanta, Inc., 552 U.S. 148 (2008).

The PSLRA imposes heightened pleading, an automatic discovery stay, a lead plaintiff process, a safe harbor for forward-looking statements, proportionate liability, and a damages cap based on a 90-day look-back.

The practical shape of the case: win the motion to dismiss or expect to settle. The discovery stay means a case that survives dismissal moves into expensive discovery with settlement pressure that most defendants cannot ignore.

Material misrepresentation or omission

Materiality, from Basic Inc. v. Levinson, 485 U.S. 224 (1988), adopting TSC Industries, Inc. v. Northway, Inc., 426 U.S. 438 (1976): a fact is material if there is a substantial likelihood that a reasonable investor would consider it important in deciding how to act, or that its disclosure would have significantly altered the total mix of information available.

For contingent or speculative events, Basic applies a probability/magnitude balancing — the indicated probability that the event will occur against the anticipated magnitude of the event in light of the totality of company activity.

Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (2011), rejected a bright-line rule that adverse event reports are immaterial absent statistical significance, holding that materiality depends on the total mix and that a reasonable investor may find non-statistically-significant information important.

Not actionable:

  • Puffery — vague, general, optimistic statements on which no reasonable investor would rely. "Strong," "robust," "world-class," "committed to excellence."
  • Immaterial statements.
  • Truth on the market — where the allegedly concealed information was already public and credibly transmitted, though this is difficult to establish at the pleading stage.

Duty to disclose. There is no general duty to disclose all material information. A duty arises where: a statute or regulation requires it; the company has made a statement that would be misleading without the omitted fact (the half-truth doctrine); insiders trade on material nonpublic information; or a prior statement has become materially misleading and a duty to update or correct arises — with courts split on the scope of the duty to update.

Macquarie Infrastructure Corp. v. Moab Partners, L.P., 601 U.S. 257 (2024), resolved an important question: a pure omission — a failure to disclose information required by Item 303 of Regulation S-K (management's discussion of known trends and uncertainties) — cannot support a Rule 10b-5(b) claim absent a statement rendered misleading by the omission. The rule prohibits omitting facts "necessary in order to make the statements made not misleading," which requires a statement. Plaintiffs must now tie an Item 303 theory to an affirmative statement.

Opinion statements. Omnicare, Inc. v. Laborers District Council Construction Industry Pension Fund, 575 U.S. 175 (2015), addressed § 11 but has been applied broadly. A sincerely held opinion is not an untrue statement of fact merely because it turns out to be wrong. An opinion may be actionable if: the speaker did not actually hold the belief; the opinion contains an embedded factual assertion that is untrue; or the opinion omits material facts about the speaker's inquiry into or knowledge concerning the statement, and those facts conflict with what a reasonable investor would take from the statement itself. The last prong is demanding — the plaintiff must identify particular facts going to the basis for the opinion whose omission makes the statement misleading in context, including the broader frame in which the opinion was offered.

Statements of legal compliance, risk factors, and internal control representations are frequent targets. A risk factor warning of a risk that has already materialized is a classic actionable statement — warning that "we may experience channel inventory buildup" when the buildup has already occurred is misleading, not cautionary.

Scienter and the PSLRA's pleading standard

Scienter means a mental state embracing intent to deceive, manipulate, or defraud, Ernst & Ernst v. Hochfelder, 425 U.S. 185 (1976). Every circuit accepts recklessness as sufficient, defined as an extreme departure from the standards of ordinary care presenting a danger of misleading buyers or sellers that is either known to the defendant or so obvious that the actor must have been aware of it. Negligence is not enough.

The PSLRA's pleading standard, 15 U.S.C. § 78u-4(b), is the most consequential provision in securities litigation:

  • The complaint must specify each statement alleged to have been misleading, the reason or reasons why it is misleading, and, where allegations are made on information and belief, all facts on which that belief is formed.
  • The complaint must, with respect to each act or omission, state with particularity facts giving rise to a strong inference that the defendant acted with the required state of mind.

Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (2007), construed "strong inference": a court must consider plausible opposing inferences, and the inference of scienter must be cogent and at least as compelling as any opposing inference of nonfraudulent intent. The analysis is holistic — the facts are weighed collectively, not item by item.

What supports scienter:

  • Contemporaneous internal documents contradicting the public statement.
  • Confidential witness accounts, subject to the discounting courts apply when witnesses are not identified with sufficient particularity to support the probability that a person in the position occupied would possess the information alleged.
  • Suspicious insider trading — sales unusual in timing and amount relative to the insider's prior trading history. Sales pursuant to a Rule 10b5-1 plan adopted before the alleged fraud substantially undercut the inference, which is why plan adoption dates matter enormously.
  • Core operations — the inference that senior management knew facts critical to the company's central business. Circuits differ on its strength; most treat it as supplementary rather than sufficient alone.
  • Magnitude and duration of the alleged misstatement.
  • Restatements, which support but do not establish scienter — GAAP violations alone are insufficient.
  • Resignations and terminations shortly after the disclosure, again as supplementary evidence.
  • Motive and opportunity, which the Second Circuit treats as one route to the inference, while other circuits treat motive as merely relevant.

What cuts against it: the absence of insider selling, or selling inconsistent with the alleged fraud; contemporaneous purchases by insiders; the company's own prompt disclosure of the problem; auditor sign-off; and an innocent explanation that is at least as compelling.

Corporate scienter. Whether and how to impute an individual's state of mind to the company divides the circuits. The dominant approach requires pleading scienter as to an individual whose statements are attributed to the company; a minority permits an inference from the dramatic nature of the misstatement itself.

Group pleading — the presumption that statements in group-published documents are attributable to officers collectively — has been rejected or questioned by most circuits after the PSLRA, requiring plaintiffs to attribute specific statements to specific speakers. Janus Capital Group, Inc. v. First Derivative Traders, 564 U.S. 135 (2011), further narrowed primary liability: the "maker" of a statement is the person or entity with ultimate authority over it, including its content and whether and how to communicate it.

Reliance and the fraud-on-the-market presumption

Individual proof of reliance would make class treatment impossible. Basic Inc. v. Levinson solved this with the fraud-on-the-market presumption: in an efficient market, material public misrepresentations are reflected in the stock price, and an investor who buys at the market price is presumed to have relied on them.

To invoke the presumption, a plaintiff must show: the alleged misrepresentation was publicly known; it was material; the stock traded in an efficient market; and the plaintiff traded between the misrepresentation and the corrective disclosure.

Market efficiency is established through the Cammer and Krogman factors: average weekly trading volume, analyst coverage, market makers and arbitrageurs, eligibility to file a Form S-3, a demonstrated cause-and-effect relationship between unexpected news and price movement, market capitalization, bid-ask spread, and public float.

Rebuttal. Halliburton Co. v. Erica P. John Fund, Inc., 573 U.S. 258 (2014) (Halliburton II), preserved Basic but held that defendants may rebut the presumption at class certification with evidence of a lack of price impact.

Goldman Sachs Group, Inc. v. Arkansas Teacher Retirement System, 594 U.S. 113 (2021), refined this materially. It held that: the generic nature of an alleged misrepresentation is relevant evidence at class certification, even though it also bears on materiality; courts should consider the mismatch between the generic quality of an alleged misstatement and the specific nature of the later corrective disclosure, because an inference of price maintenance is weaker where the two do not match; and defendants bear the burden of persuasion on price impact by a preponderance of the evidence.

Price maintenance is the theory that carries most modern cases. Where a false statement does not move the price up but maintains an already-inflated price, the corrective disclosure produces the drop. Goldman makes this theory harder to sustain where the alleged misstatements are generic.

Affiliated Ute. For claims based primarily on omissions, Affiliated Ute Citizens v. United States, 406 U.S. 128 (1972), supplies a presumption of reliance without the efficiency showing — but courts limit it to genuine omission cases, which after Macquarie are narrower still.

Loss causation and damages

Loss causation is a separate element and a statutory requirement, 15 U.S.C. § 78u-4(b)(4). Dura Pharmaceuticals, Inc. v. Broudo, 544 U.S. 336 (2005), held that inflated purchase price alone is not loss — the plaintiff must allege and prove that the relevant truth was revealed and caused the decline.

Proving it:

  • A corrective disclosure revealing the concealed truth, followed by a statistically significant price decline. The disclosure need not come from the company; analyst reports, short-seller reports, government actions, and news coverage can qualify if they reveal the concealed facts rather than merely repackaging public information.
  • Materialization of a concealed risk — the concealed condition manifests in events that drive the price down, without a single revelatory disclosure.

Event study analysis is required in practice. The expert must isolate the effect of the corrective disclosure from market-wide and industry movements, and must confront confounding information disclosed simultaneously. Most earnings-related corrective disclosures come bundled with other news, and disaggregating them is where the damages fight occurs.

Damages are typically the out-of-pocket measure — the difference between the price paid and the true value at purchase, measured by per-share inflation on the purchase and sale dates. The PSLRA imposes a cap: damages may not exceed the difference between the purchase or sale price and the mean trading price during the 90-day period following the corrective disclosure, 15 U.S.C. § 78u-4(e), with a shorter period where the plaintiff sells earlier.

Proportionate liability, 15 U.S.C. § 78u-4(f), replaces joint and several liability for defendants who did not knowingly commit a violation, allocating responsibility by percentage of fault — with a limited exception ensuring recovery for smaller investors.

Statute of limitations, 28 U.S.C. § 1658(b): the earlier of two years after discovery of the facts constituting the violation or five years after the violation. Merck & Co. v. Reynolds, 559 U.S. 633 (2010), held that discovery includes facts constituting the violation that a reasonably diligent plaintiff would have discovered, including scienter. The five-year period is a statute of repose not subject to equitable tolling, California Public Employees' Retirement System v. ANZ Securities, Inc., 582 U.S. 497 (2017), which held that American Pipe tolling does not extend the § 13 repose period — a holding with direct implications for opt-out plaintiffs.

The PSLRA's procedural machinery

The automatic discovery stay, 15 U.S.C. § 78u-4(b)(3)(B). All discovery and other proceedings are stayed during the pendency of any motion to dismiss, unless the court finds particularized discovery necessary to preserve evidence or to prevent undue prejudice. This is the single most valuable defense provision: the defendant briefs dismissal without producing a document, and a case that fails at the pleading stage costs a fraction of ordinary litigation.

The stay does not relieve the parties of preservation obligations — the statute expressly requires parties to preserve evidence relevant to the allegations, and a litigation hold must issue immediately.

Lead plaintiff, 15 U.S.C. § 78u-4(a)(3). The first plaintiff to file publishes notice within 20 days; class members may move for appointment within 60 days. The court appoints the most adequate plaintiff, with a rebuttable presumption in favor of the movant with the largest financial interest who otherwise satisfies Rule 23. The design was to displace lawyer-driven litigation with institutional investors, and pension funds now lead most significant cases. Lead plaintiff then selects lead counsel, subject to court approval.

Certification requirement. The plaintiff must file a sworn certification stating that they reviewed the complaint, did not purchase at the direction of counsel, are willing to serve, listing transactions in the security, and identifying other actions in which they sought lead plaintiff status in the prior three years — with a limit of five in three years absent good cause, aimed at professional plaintiffs.

Sanctions review. At final adjudication the court must make findings on each party's and attorney's compliance with Rule 11(b), with a presumption that the sanction for a substantial failure is an award of the opposing party's full attorney's fees.

The safe harbor for forward-looking statements, 15 U.S.C. § 78u-5. A forward-looking statement is not actionable if it is identified as such and accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially — or if the plaintiff fails to prove the statement was made with actual knowledge of its falsity.

Points that matter:

  • The two prongs are independent. A statement with adequate cautionary language is protected regardless of the speaker's state of mind.
  • Cautionary language must be meaningful and specific to the company's actual risks. Boilerplate does not qualify, and language identical to the prior year's may be found not to have been updated for known risks.
  • The safe harbor does not apply to statements of historical fact, to statements in financial statements prepared under GAAP, to IPO and certain other offerings, or to statements by issuers subject to specified disqualifications.
  • The bespeaks caution doctrine, its judicial cousin, applies similarly at common law.
  • The mixed statement problem: a sentence containing both a forward-looking projection and an assertion of present fact is protected only as to the former.

Securities Act claims: Sections 11 and 12

Claims under the Securities Act of 1933 arise from registered offerings and are structurally easier for plaintiffs.

Section 11, 15 U.S.C. § 77k. A registration statement containing an untrue statement of material fact or omitting a material fact required to be stated or necessary to make statements not misleading. Defendants include the issuer, every person who signed, every director, every named expert as to their portion, and the underwriters.

No scienter. No reliance (except where the plaintiff acquired after an earnings statement covering 12 months post-effective). No loss causation as an element — instead, negative causation is an affirmative defense on which the defendant bears the burden. The issuer is strictly liable. Other defendants have a due diligence defense requiring reasonable investigation and reasonable ground to believe the statements were true.

Standing requires tracing the shares to the defective registration statement — a serious obstacle where registered and unregistered shares trade together, and one the Supreme Court reinforced in Slack Technologies, LLC v. Pirani, 598 U.S. 759 (2023), holding that a § 11 plaintiff must plead and prove the shares purchased were registered under the challenged registration statement, which is a substantial barrier for direct listings.

Section 12(a)(2), 15 U.S.C. § 77l(a)(2), provides rescission against a statutory seller for a material misstatement in a prospectus or oral communication, limited by Gustafson v. Alloyd Co., 513 U.S. 561 (1995), to public offerings.

Section 12(a)(1) provides rescission for the sale of an unregistered security in violation of § 5 — a strict liability claim that is the reason exemption analysis matters so much.

Forum. Cyan, Inc. v. Beaver County Employees Retirement Fund, 583 U.S. 416 (2018), held that state courts retain concurrent jurisdiction over class actions asserting only 1933 Act claims and that such actions are not removable — which produced parallel state and federal litigation until issuers responded with federal forum provisions in their charters, upheld in Salzberg v. Sciabacucchi, 227 A.3d 102 (Del. 2020).

Limitations: one year from discovery, three years from the offering (a repose period), 15 U.S.C. § 77m.

Class certification, settlement, and insurance

Certification under Rule 23(b)(3) is where price impact is litigated. Predominance turns on the availability of the Basic presumption; if it is rebutted, individual reliance issues predominate and the class fails. Comcast Corp. v. Behrend, 569 U.S. 27 (2013), requires a damages model consistent with the liability theory, though in securities cases the out-of-pocket model is standard and rarely defeats certification on its own.

Certification is usually the last real gate. A certified class with a plausible damages model produces settlement pressure that few public companies accept the risk of testing at trial — securities class actions almost never go to verdict.

Settlement dynamics. Settlement values correlate with the estimated damages, the strength of the scienter allegations, whether the company restated, whether there is a parallel SEC action, and the available D&O limits. Approval requires Rule 23(e) findings, notice, a claims administration process, and a fee award — typically a percentage of the fund, with courts scrutinizing the claims rate and the allocation plan.

D&O insurance determines what a settlement can look like.

  • Side A covers individual directors and officers where the company cannot indemnify — including in bankruptcy and where indemnification is barred by law. Often supplemented by a dedicated Side A DIC policy.
  • Side B reimburses the company for indemnification.
  • Side C ("entity coverage") covers the company itself, and for public companies is typically limited to securities claims — which is precisely why it matters here.

Points to check before a claim arises: the claims-made trigger and notice provisions; the definition of claim and whether an SEC informal inquiry qualifies; the allocation provision between covered and uncovered matters; the conduct exclusions for fraud and personal profit, and whether they require a final, non-appealable adjudication (they should); the insured versus insured exclusion and its carve-outs for derivative and bankruptcy trustee actions; severability of the application and of the exclusions; consent to settle and defense cost advancement; and whether limits erode with defense costs, which in a multi-year securities case they will.

Related proceedings almost always follow: shareholder derivative actions alleging breach of fiduciary duty and failure of oversight; books and records demands under Delaware § 220, which are increasingly the first move; SEC investigations; and, in a small number of cases, criminal inquiries.

Defense strategy

Immediately.

  1. Litigation hold — the PSLRA stay does not excuse preservation.
  2. Notice to D&O carriers on every potentially applicable tower and policy year, in the form the policy requires.
  3. Convene the audit committee or a special committee where insiders are implicated.
  4. Preserve and analyze Rule 10b5-1 plan documentation, including adoption dates.
  5. Assess disclosure obligations relating to the litigation itself.

The motion to dismiss is the case. Attack, in order:

  • Actionability — puffery, forward-looking statements within the safe harbor, opinions under Omnicare, and, after Macquarie, any pure-omission theory untethered from a statement.
  • Falsity — pleaded with particularity, statement by statement, with the reason each was false when made. Fraud by hindsight is not a claim.
  • Scienter — the holistic Tellabs weighing, with the innocent inference developed affirmatively: no unusual insider sales, sales under pre-existing 10b5-1 plans, prompt disclosure, auditor concurrence, contemporaneous insider purchases.
  • Loss causation — the corrective disclosure did not reveal the alleged fraud, or the decline is attributable to confounding disclosures.
  • Standing and tracing for 1933 Act claims.
  • Limitations and repose.

If dismissal fails, the fight moves to class certification and price impact, where Goldman supplies the argument that generic statements did not maintain price inflation and that the mismatch between the alleged misstatements and the corrective disclosure defeats the inference. Retain the event study expert early; this is the most expert-dependent phase of the case.

Coordinate with the derivative action, the books and records demand, and any SEC investigation. Positions taken in one proceeding will be used in the others, and a company that describes an event differently to the SEC than in its motion to dismiss has created a problem it cannot fix.

Frequently asked questions

We missed guidance and the stock dropped. Are we going to be sued? A significant unexpected decline with a prior period of optimistic statements is the standard fact pattern. Whether a suit is filed is largely a function of the size of the decline and the market capitalization.

Is "we are confident in our pipeline" actionable? Standing alone, generally not — it is puffery. In context, alongside specific factual assertions or where the speaker knew the pipeline had collapsed, it can be.

Do our risk factors protect us? Only if they are meaningful, specific, and address the risk as it actually stood. A warning that a risk "may" occur when it already has is a misstatement, not a shield.

Can our CFO be personally liable? Yes, as the maker of statements under Janus, and individuals are routinely named. This is what Side A coverage exists for.

We restated our financials. Does that establish fraud? No. A restatement supports falsity but not scienter; GAAP violations alone are insufficient under settled law.

Our executives sold stock during the class period. The question is whether the sales were unusual in timing and amount relative to their history, and whether they were made under a 10b5-1 plan adopted before the alleged fraud began. Plan documentation is critical evidence.

How long until we know whether the case survives? Consolidation and lead plaintiff appointment take a few months; an amended complaint follows; briefing and decision on dismissal commonly bring the total to twelve to eighteen months — during which discovery is stayed.

What drives settlement value? Estimated classwide damages, the strength of the scienter allegations, whether a restatement occurred, parallel government action, and the D&O limits available.

Conclusion

Securities fraud litigation is procedural in a way that few other areas are. The substantive question — did the company mislead investors — is answered late and rarely by a jury. What decides these cases is whether the complaint pleads scienter with enough particularity to clear Tellabs, whether the challenged statements are actionable at all, and whether the defendant can sever the link between the statements and the price.

Two practical implications follow. For a public company, the disclosure controls that prevent these cases are the same ones that produce a defensible record: specific and updated risk factors, cautionary language tied to actual risks, 10b5-1 plans adopted well in advance and documented, and a discipline against optimistic characterizations that internal reporting contradicts.

For counsel, the case is the motion to dismiss. Everything before it is preservation and insurance; everything after it is settlement.

Insider trading and Section 16

Two adjacent regimes travel with every Rule 10b-5 analysis, and public company counsel are asked about them constantly.

Insider trading is prosecuted under the same § 10(b) and Rule 10b-5. Two theories:

  • Classical. A corporate insider who trades on material nonpublic information breaches a duty to the shareholders with whom they trade, Chiarella v. United States, 445 U.S. 222 (1980).
  • Misappropriation. A person who trades on confidential information in breach of a duty owed to the source of the information — an employer, a client, a family member — commits fraud on that source, United States v. O'Hagan, 521 U.S. 642 (1997). This is how lawyers, bankers, printers, and consultants are reached.

Tipping liability, Dirks v. SEC, 463 U.S. 646 (1983), requires that the insider breach a duty by disclosing for a personal benefit, and that the tippee know or should know of the breach. Salman v. United States, 580 U.S. 39 (2016), confirmed that a gift of confidential information to a trading relative or friend is itself a personal benefit, and no pecuniary gain need be shown.

Rule 10b5-1 provides an affirmative defense for trades made pursuant to a plan adopted before becoming aware of material nonpublic information, specifying amounts, prices, and dates or supplying a formula, and precluding subsequent influence over execution. Amended rules added cooling-off periods between adoption and the first trade, a good faith operation requirement, director and officer certifications, restrictions on overlapping plans and on single-trade plans, and disclosure of plan adoption, modification, and termination in periodic reports. Plans adopted under the current requirements are substantially stronger evidence in a securities case than plans under the old rule, which is a reason to refresh them.

Regulation FD, 17 C.F.R. §§ 243.100-243.103, prohibits selective disclosure of material nonpublic information to securities professionals and holders likely to trade, requiring simultaneous public disclosure for intentional disclosures and prompt disclosure for unintentional ones. It is a frequent source of enforcement following investor conferences and one-on-one meetings.

Section 16 of the Exchange Act applies to directors, officers, and ten percent beneficial owners of registered classes: Forms 3, 4, and 5 reporting, with Form 4 due within two business days; short-swing profit disgorgement under § 16(b) for any purchase and sale within six months, enforceable by the issuer or by any shareholder derivatively, on a strict liability basis with no intent element and no defense that the insider had no inside information; and a prohibition on short sales by insiders under § 16(c).

Rule 144 governs resales of restricted and control securities, and Rule 10b-18 provides a safe harbor for issuer repurchases as to manner, timing, price, and volume.

The practical point for counsel: a securities class action complaint will recite every Form 4 filed during the class period, and the pattern of those filings will do more to shape the scienter inference than anything the company says about them afterward.

Related articles

This article is provided for general informational purposes and does not constitute legal advice. Securities litigation doctrine develops continuously and differs by circuit on corporate scienter, the duty to update, and other issues. Consult qualified securities litigation counsel promptly upon a significant stock decline or the filing of a complaint.